[Adjunct use of NovoSeven (recombinant factor VIIa) for penetrating cardiac trauma].

نویسندگان

  • Luis Manuel García-Núñez
  • Luis Enrique Soto-Ortega
  • Ruy Cabello-Pasini
  • Luis Enrique Payró-Hernández
  • Ignacio Javier Magaña-Sánchez
چکیده

BACKGROUND Uncontrolled bleeding leads to 40-86% of preventable deaths due to trauma. Use of NovoSeven (rFVIIa) in trauma is promising, although data supporting its utilization are limited. CASE REPORT We report the case of a patient who sustained a penetrating grade V cardiac injury (AAST-OIS) and presented postoperative massive coagulopathic bleeding arrested by the administration of platelet pools and NovoSeven. DISCUSSION This report represents our initial experience and the very first case of successful use of NovoSeven for the treatment of traumatic coagulopathic hemorrhage at the Central Military Hospital in Mexico City. A further prospective trial justifying its use in our institution is warranted.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.

BACKGROUND Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes. METHODS We performed a phase 3 randomized clinical trial evaluating efficacy and safety of rFVIIa as an adjunct to direct hemostasis in major trauma. We stud...

متن کامل

The effect of recombinant factor VIIa (NovoSeven(R)) on peri-operative bleeding during total knee replacement in a non-hemophiliac patient.

Background. Recombinant factor VIIa has been in use for some time to control bleeding in persons with hemophilia. In the present study we describe our experience with the use of a commercial form of recombinant factor VIIa, NovoSeven(R) (Novo Nordisk, Denmark), to control perioperative bleeding in the course of total knee replacement on a patient who, though not hemophiliac, had a very low tole...

متن کامل

NovoSeven: Cleveland Clinic Guidelines

In This Issue: • NovoSeven • Therapeutic Interchanges Introduction: Recombinant human activated Factor VII (rFVIIa), or NovoSeven, is a hemostatic agent which is structurally similar to human plasma-derived coagulation Factor VIIa. Recombinant FVIIa is currently licensed by the US Food and Drug Administration (FDA) in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX o...

متن کامل

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).

CARDIAC surgery with cardiopulmonary bypass (CPB) poses serious hemostatic challenges in Jehovah’s Witnesses, who refuse blood transfusions on religious grounds. Excessive bleeding ( 2 l) after cardiac surgery is encountered in 5–7% of Jehovah’s Witness patients, and necessitates reexploration in 3.6% of cases. Recombinant factor VIIa (rFVIIa, NovoSeven®; Novo Nordisk, Princeton, NJ), produced ...

متن کامل

Factor Viia (recombinant) (novoseven®) in Trauma

EVIDENCE DEFINITIONS • Class I: Prospective randomized controlled trial. • Class II: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies. • Class III: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion. • Technology assessment: A technology study which doe...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Cirugia y cirujanos

دوره 76 1  شماره 

صفحات  -

تاریخ انتشار 2008